Lord Moylan

The Government is committed to extending mandatory pay gap reporting to ethnicity and disability pay gaps for employers with at least 250 employees. It is also committed to ensuring the Public Sector Equality Duty covers all parties exercising public functions.

The information requested falls under the remit of the UK Statistics Authority.

Please see the letter attached from the Director General for Office for Statistics Regulation.

Ed Humpherson, Director General for Office for Statistics Regulation

The Lord Moylan
House of Lords
London
SW1A 0PW

19 December 2024

Dear Lord Moylan,

As Director General for Office for Statistics Regulation, I am responding to your Parliamentary Question asking when His Majesty's Government plan to update the assessment of abortion statistics by the UK Statistics Authority in order to comply with the Code of Practice for Statistics (HL3549).

The Office for Statistics Regulation (OSR) was established in 2016 and is the regulatory arm of the UK Statistics Authority (the Authority). OSR provides independent regulation of all official statistics produced in the UK. Before 2016, the Authority's Monitoring and Assessment team handled regulatory functions.

Accredited Official Statistics are official statistics that have been independently assessed by OSR to comply with the standards of trustworthiness, quality and value in the Code of Practice for Statistics. Accredited Official Statistics are called National Statistics in the Statistics and Registration Service Act 2007.

Abortions Statistics for England and Wales produced by the Office for Health Improvement & Disparities (OHID, was previously Department of Health) were assessed as complying with the Code of Practice for Statistics in February 2012, and National Statistics designation was awarded[1].

It is a requirement of the Statistics and Registration Service Act 2007 that the Code of Practice must continue to be complied with by the statistics producer in relation to the statistics. OSR regularly engages with the Head of Profession for Statistics for the Department of Health and Social Care to obtain general assurance on the Department’s compliance with the Code of Practice, but the OSR team has not discussed the abortion statistics specifically in these conversations.

Once a set of statistics has been assessed, OSR can re-assess them at any time. Reassessments can be initiated as a result of concerns raised with us by users, including citizens, academic experts and policy stakeholders. While we do not currently have any plans to re-assess the abortion statistics in this financial year, we are always open to hearing the concerns of people with an interest in the topic area.

To that end, if you have any concerns regarding the trustworthiness, quality and value of these abortion statistics not complying with the Code of Practice for Statistics, please do contact me through our general contact email regulation@statistics.gov.uk.

Yours sincerely

Ed Humpherson
Director General for OSR

[1]Statistics on Abortion: Letter of Confirmation as National Statistics, https://uksa.statisticsauthority.gov.uk/publication/statistics-on-abortion-letter-of-confirmation-as-national-statistics/

The impugned legislation in Podchasov v. Russia is not directly comparable to the Online Safety Act, which contains robust protections for privacy and freedom of expression. A memorandum on ECHR compatibility was published during Bill passage.

Section 121 of the Act contains stringent safeguards ensuring that Ofcom’s power to issue Technology Notices, including relating to child sexual exploitation and abuse (CSEA) content communicated privately, can only be used when necessary and proportionate. Ofcom must consider a range of matters, including whether there are less intrusive alternatives, the harm to individuals and the required technology’s ability to achieve the purpose described.

The Charity Commission’s role as the independent regulator of charities in England and Wales is to ensure that charity trustees comply with their duties as set out in charity law. The Charity Commission has published guidance for trustees on the use of social media and managing the risks for charities.

The Charity Commission notes the Tribunal’s judgment in this recent case, and is considering what lessons can be applied to future casework.

In the last five years, the Charity Commission has disqualified six individuals in cases that relate to the usage of social media. An individual’s use of social media was the sole basis for disqualification in three cases, while in the other three it was one of several grounds.

The Commission’s decisions to disqualify are subject to robust oversight and can be appealed through review by an independent member of Commission staff, and subsequently to the First Tier Tribunal.

The Charity Commission is independent from the Government in its regulatory decision making.

Departmental settlements have been set following the Budget announcement on October 30. Individual programmes will now be assessed during the departmental Business Planning process.

Network Rail is responsible for assessing the availability of specialist rail plant used in maintaining the rail network. It is currently reviewing its long-term equipment requirements for track maintenance and renewals, to ensure that it has the capacity, flexibility, and technology it needs to meet future demand efficiently.

Officials continue to develop the proposition for the Great British Railways app and website. We are engaging with industry on this project and will provide updates in due course.

Great British Railways’ (GBR’s) licence will require it to comply with the code of practice, which will be owned and managed by the Office of Road and Rail (ORR).

To ensure that GBR abides by the rules set out in the code of practice, affected third parties will be able challenge any decisions or actions they consider to be noncompliant, by raising them directly with the ORR. The ORR will be required to investigate and, if it considers that GBR has not complied, it will be able to demand corrective action by issuing binding orders on GBR.

The Government intends to publish the Road Safety Strategy this year.

The Government is committed to a fair and open rail retail market, in which Great British Railways (GBR) will sell tickets alongside, and compete with, independent retailers. Moreover, the retail industry management functions currently performed by the Rail Delivery Group will move to GBR.

To ensure fairness when GBR takes on these functions, the Government has announced a range of safeguards, including an industry code of practice. The code of practice will incorporate clear requirements for how GBR interacts with all market participants and impose separation of decision-making where relevant. It will be owned and managed by the Office of Rail and Road, and GBR’s licence will require compliance with it.

A number of National Health Service treatment options are available for patients with mantle cell lymphoma, and may include:

- chemotherapy plus rituximab;

- autologous stem cell transplant;

- ibrutinib;

- zanubrutinib;

- brexucabtagene autoleucel, a type of chimeric antigen receptor T-cell therapy; and/or

- supportive care.

None of these treatments are precluded on the basis of ethnicity, age, or a combination of the two, but available options will be dependent on individual clinical circumstances and any prior treatment or treatments received.

Potential treatment options are also currently being appraised by the National Institute for Health and Care Excellence and therefore could be made available within England in the future, subject to positive recommendations on NHS adoption being reached. These are: Acalabrutinib with bendamustine and rituximab; and Ibrutinib with R-CHOP.

202 patients have received brexucabtagene autoleucel, a form of CAR-T therapy, for the treatment of mantle cell lymphoma via the Cancer Drugs Fund (CDF). This data is taken from NHS England’s prior approval system. The National Institute for Health and Care Excellence (NICE) is currently re-evaluating the evidence on clinical outcomes collected through its use in the CDF in its ongoing re-evaluation of brexucabtagene autoleucel.

NICE published final draft guidance on 24 December 2025 in which it was not able to recommend brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma in adults who have had two or more lines of systemic treatment that included a Bruton's tyrosine kinase inhibitor. This is because the extent of brexucabtagene autoleucel’s clinical benefit is uncertain. There are also uncertainties in the economic model because there is not enough evidence to tell if the cancer can be ‘cured’ in people having brexucabtagene autoleucel and it is not known how long people live after having brexucabtagene autoleucel. The cost-effectiveness estimates are also substantially above the range that NICE considers an acceptable use of National Health Service resources. NICE has not yet published final guidance and stakeholders have recently had an opportunity to appeal NICE’s recommendations.

The Government recognises that the potential withdrawal of brexucabtagene autoleucel as a treatment for future patients will be concerning for patients and their families, but it is right that these decisions are taken independently and on the basis of the available evidence. In line with an arrangement between NHS England and the company, if NICE’s final guidance does not recommend use, patients who started treatment during the managed access period can continue their treatment.

202 patients have received brexucabtagene autoleucel, a form of CAR-T therapy, for the treatment of mantle cell lymphoma via the Cancer Drugs Fund (CDF). This data is taken from NHS England’s prior approval system. The National Institute for Health and Care Excellence (NICE) is currently re-evaluating the evidence on clinical outcomes collected through its use in the CDF in its ongoing re-evaluation of brexucabtagene autoleucel.

NICE published final draft guidance on 24 December 2025 in which it was not able to recommend brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma in adults who have had two or more lines of systemic treatment that included a Bruton's tyrosine kinase inhibitor. This is because the extent of brexucabtagene autoleucel’s clinical benefit is uncertain. There are also uncertainties in the economic model because there is not enough evidence to tell if the cancer can be ‘cured’ in people having brexucabtagene autoleucel and it is not known how long people live after having brexucabtagene autoleucel. The cost-effectiveness estimates are also substantially above the range that NICE considers an acceptable use of National Health Service resources. NICE has not yet published final guidance and stakeholders have recently had an opportunity to appeal NICE’s recommendations.

The Government recognises that the potential withdrawal of brexucabtagene autoleucel as a treatment for future patients will be concerning for patients and their families, but it is right that these decisions are taken independently and on the basis of the available evidence. In line with an arrangement between NHS England and the company, if NICE’s final guidance does not recommend use, patients who started treatment during the managed access period can continue their treatment.

The National Institute for Health and Care Excellence (NICE) evaluates all newly licensed cancer medicines and may recommend promising treatments for use through the Cancer Drugs Fund (CDF) where there is too much clinical uncertainty for routine commissioning. Under these arrangements, cancer medicines are made available to National Health Service patients for a defined period while further real‑world evidence is collected to address the uncertainties identified in NICE’s original appraisal.

At the end of the managed access period, NICE undertakes a full re‑appraisal of the medicine. This re‑appraisal considers all the evidence gathered during CDF use alongside updated clinical and cost‑effectiveness analyses. NICE then determines whether the medicine should be routinely funded by the NHS, or whether it cannot be recommended for routine commissioning. This re‑appraisal process is one of the limited circumstances in which NICE routinely re‑evaluates previous decisions.

In 2022, NICE updated its methods and replaced the earlier end‑of‑life flexibilities with the severity modifier. As a result, re‑appraisals of cancer medicines that originally entered the CDF under end‑of‑life criteria are now conducted in line with NICE’s current methods framework, ensuring consistency, fairness, and opportunity‑cost neutrality across all appraisals. NICE has recommended 96% of the medicines that it has re-appraised following a period of managed access for routine NHS use. Where NICE is unable to recommend a medicine for routine use following the period of managed access, it remains available for existing patients but is no longer routinely funded for new patients.

In accordance with the Abortion Act 1967, all abortions in England must be notified to the Chief Medical Officer within 14 days of the procedure. This information is used by the Department to monitor compliance with the act. The Department also publishes this data in line with the Code of Practice for Statistics, to ensure it is available to commissioners and providers of abortion services and others with an interest in abortion in England and Wales. There is no legal duty placed on the Department to publish data collected through abortion notification forms.

The Department regularly consults the Office for Statistics Regulation, which is the independent regulatory arm of the UK Statistics Authority, and provides independent regulation of all official statistics produced in the United Kingdom.

The UK champions Freedom of Religion or Belief for all, and we maintain that no one should live in fear because of what they do or do not believe. We engage on these issues with the Moroccan Government and authorities on a regular basis.

The UK is committed to championing Freedom of Religion or Belief. We highlight this issue at the UN, via the G7 and as a member of the Article 18 Alliance. Our Embassy in Ashgabat has contact with representatives of different faith groups, as well as visiting UK faith representatives, to discuss issues they face in practicing their religion in Turkmenistan. In Turkmenistan's most recent UN Universal Periodic Review in 2023, the UK raised concerns about freedom of association. We continue to seek opportunities to raise concerns at the UN and other international fora, where appropriate.

Intercommunal violence has a devastating effect on communities. The root causes are complex and frequently relate to competition over resources, historical grievances, and criminality.  We are supporting Nigeria to tackle these root causes through our Strengthening Peace and Resilience in Nigeria (SPRiNG) programme and continue to engage in local and national peace-building efforts. British High Commission officials met with government representatives, traditional rulers and stakeholders across civil society in Benue State in July 2025.

The UK-Nigeria Security and Defence Partnership (SDP) is building capacity in Nigeria's security forces to tackle violence against all civilian communities, including religious communities. The former Minister for Africa discussed intercommunal violence with Nigerian ministers and officials during his visit in May 2025. Our officials in Abuja continue to engage with the Nigerian government and religious leaders on freedom of religion and belief.

The UK-funded Bangladesh Collaborative, Accountable and Peaceful Politics programme works to protect and promote freedom of religion or belief. A local peace building organisation The Hunger Project has organised a range of initiatives to foster inter-ethnic and religious peace. This has included peace events, consultation meetings with local authorities and quarterly meetings with local conflict mediation. As a result, local peace forum groups have been created to take steps to protect Hindus and other minority communities during their religious festivals. The UN Human Rights Office have now published their report; this provides credible independent data on events last year.

While the UK Government condemns all violence, including kidnaps, across Nigeria we do not routinely engage on instances of non-UK citizens being kidnapped as this is a matter for the Nigerian authorities. Kidnapping for ransom is sadly a widespread practice in Nigeria, particularly in the North-West where banditry is prevalent. Kidnappings often have financial rather than religious motives and communities of all religions and beliefs are vulnerable. With assistance from the UK National Crime Agency, a Multi-Agency Kidnap Fusion Cell (MAKFC) has been established to support cooperation between Nigeria's security and justice agencies. This will both reduce the harm to victims and hold those responsible to account.

By the end of January 2024, over 11.5m tax returns had been submitted for the 2022/23 financial year. Around 97 percent of returns received were online and the majority were processed automatically.

HMRC carries out additional processing work on a small percentage of tax returns. This includes checks, addressing amends made by customers and manually working through returns which are made on paper. This year HMRC is on track to meet targets for processing paper Self Assessment returns which is consistent with previous years.

To ensure taxpayers get support to meet their obligations for filing 23/24 returns, HMRC has recently recruited and trained additional customer service advisors.

HM Revenue and Customs (HMRC) launched its first strategy to tackle illicit tobacco in 2000. This, and consequent strategies with Border Force, have reduced the overall tobacco duty tax gap from 21.7% in 2005/6 to 14.5% in 2022/23.

During this time, the duty gap for cigarettes has reduced by a third, and for hand-rolling tobacco by a half.

In January this year HMRC and Border Force published their latest illicit tobacco strategy, ‘Stubbing Out the Problem’. This Government is committed to reducing the trade in illicit tobacco with a focus on reducing demand, and tackling and disrupting the organised crime groups behind the illicit tobacco trade.

The tobacco strategy is supported by £100 million of new smokefree funding over the next 5 years to boost existing HMRC and Border Force enforcement capability.

Under the assumptions used in tobacco costings certified by the Office for Budget Responsibility (OBR) at Spring Budget 2024, increasing overall tobacco duty rates increases tobacco duty receipts.

Tobacco duty aims to raise revenue and reduce harm to public health by discouraging smoking and raised £10bn in 2022/23. High duty rates, making tobacco less affordable, have helped reduce smoking prevalence with the percentage of adult smokers in the UK reducing from 26% in 2000 to 12% in 2023.

Strong enforcement is essential in tackling the illicit tobacco market and minimising the tax gap. HM Revenue and Customs (HMRC) and Border Force published a new illicit tobacco strategy in January 2024, ‘Stubbing Out the Problem)’. This set out the Government’s continued commitment to reduce the trade in illicit tobacco with a focus on reducing demand, and the disruption of organised crime groups behind the illicit tobacco trade.

The strategy is supported by £100 million of new ‘smokefree’ funding over the next 5 years which will boost existing HMRC and Border Force enforcement capability.

Under the assumptions used in tobacco costings certified by the Office for Budget Responsibility (OBR) at Spring Budget 2024, increasing overall tobacco duty rates increases tobacco duty receipts.